Kioni Holdings Limited filed its Form 10-Q for the quarterly period ended September 30, 2026, disclosing a third-quarter net profit of $20,343 against a nine-month net loss of $116,663.
Falcon's Beyond Global, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC on November 12, 2026, disclosing going concern uncertainty and reporting on operations across its three business lines.
BTCS Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC on November 12, 2026, reporting a net income of $54,532,771 for the third quarter and a net loss of $49,534,778 for the nine months ended September 30, …
Capstone Holding Corp. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 12, 2026, reporting a net loss of $632 thousand for the third quarter and disclosing year-over-year revenue growth alongside a rising accumulated deficit.
Lumexa Imaging Holdings, Inc. filed its quarterly report on Form 10-Q with the SEC on November 12, 2026, covering the three and nine months ended September 30, 2026, disclosing a return to profitability versus a net loss in the prior-year comparable periods.
Grace Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 12, 2026, disclosing operational and regulatory developments related to its lead drug candidate GTx-104.
DPC Holdings PLC filed its Form 10-Q for the quarterly period ended September 27, 2026 with the U.S. Securities and Exchange Commission on November 12, 2026, reporting a third-quarter net income of $31.8 million alongside a nine-month net loss of $146.8 million.
Charlotte's Web Holdings, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 12, 2026, reporting a net loss of $3.458 million for the third quarter and disclosing a significant mid-year conversion of its convertible debenture …
LASE Corp. filed a Form 10-Q with the SEC on November 12, 2026, covering the quarterly period ended September 30, 2026, reporting a net loss of $2,516,509 for the three months ended that date.
Artelo Biosciences, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 12, 2026, reporting a net loss of $1.768 million for the third quarter and a significant increase in cash and cash equivalents compared to …